Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Jade Biosciences, Inc.AVTE · Entity 4757 | Director · CHIEF EXECUTIVE OFFICER | May 16, 2024 | May 17, 2024 |
| Protara Therapeutics, Inc.PRTO · Entity 6203 | Director · President and CEO | January 31, 2019 | February 04, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Jade Biosciences, Inc.
Report date May 16, 2024 · Filed May 17, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2024-05-16 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2024-05-16 · Exercise / conversion · Acquired 10,000 · Balance 10,000 F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 27, 2023. Row 2 · 2024-05-16 · Sale · Disposed 8,707 · Balance 1,293 F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 27, 2023. F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $20.87 to $21.84, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Row 3 · 2024-05-16 · Sale · Disposed 1,293 · Balance 0 F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 27, 2023. F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $21.87 to $22.035, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.14 · Expires 2031-04-01 | Direct | 343,381 |
Reported balance
After 2024-05-16 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-05-16 · Exercise / conversion · Disposed 10,000 · Balance 343,381 F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 27, 2023. F4: A total of 493,381 shares subject to an employee stock option were granted on April 2, 2021, with 25% vested on June 4, 2022, with the remainder vesting in 36 substantially equal monthly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 27, 2023.
F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $20.87 to $21.84, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $21.87 to $22.035, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F4: A total of 493,381 shares subject to an employee stock option were granted on April 2, 2021, with 25% vested on June 4, 2022, with the remainder vesting in 36 substantially equal monthly installments thereafter.
Protara Therapeutics, Inc.
Report date January 31, 2019 · Filed February 04, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.70 · Expires 2029-01-30 | Direct | 350,000 |
Reported balance
After 2019-01-31 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-01-31 · Grant · Acquired 350,000 · Balance 350,000 F1: The options were granted on January 31, 2019 and the shares underlying this option vest 25% on the first anniversary of the grant date and the remaining shares vest in twelve equal quarterly installments. |
Filing footnotes · ownership attribution and instrument terms
F1: The options were granted on January 31, 2019 and the shares underlying this option vest 25% on the first anniversary of the grant date and the remaining shares vest in twelve equal quarterly installments.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 03, 2023 Filed Jan 5, 2023 22:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 15 | $29.82 | $447.30 |
DisclosureSEC source: 0001415889-23-000551 · form4-01052023_050101.xml · nonDerivative · entry 5 NOYES TIMOTHY P · CIK 0001185035 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 18, 2022. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 22:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 791 | $28.78 | $22,761.74 |
DisclosureSEC source: 0001415889-23-000551 · form4-01052023_050101.xml · nonDerivative · entry 4 NOYES TIMOTHY P · CIK 0001185035 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 18, 2022. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.56 to $29.40, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 22:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 2,267 | $27.90 | $63,255.65 |
DisclosureSEC source: 0001415889-23-000551 · form4-01052023_050101.xml · nonDerivative · entry 3 NOYES TIMOTHY P · CIK 0001185035 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 806 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 18, 2022. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $27.32 to $28.29, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 22:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 11,927 | $26.80 | $319,611.40 |
DisclosureSEC source: 0001415889-23-000551 · form4-01052023_050101.xml · nonDerivative · entry 2 NOYES TIMOTHY P · CIK 0001185035 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,073 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 18, 2022. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $26.26 to $27.17, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 22:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionCommon Stock | 15,000 | $2.14 | $32,100.00 |
DisclosureSEC source: 0001415889-23-000551 · form4-01052023_050101.xml · nonDerivative · entry 1 NOYES TIMOTHY P · CIK 0001185035 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 18, 2022. Read SEC document |
| December 01, 2022 Filed Dec 3, 2022 00:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001415889-22-011983 · form4-12022022_071207.xml · derivative · entry 3 NOYES TIMOTHY P · CIK 0001185035 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 478,381 Underlying: Common Stock · 15,000 shares Expires 2031-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 18, 2022. F2 · derivative.exercise_date: A total of 493,381 shares subject to an employee stock option were granted on April 2, 2021, with 25% vested on June 4, 2022, with the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| December 01, 2022 Filed Dec 3, 2022 00:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 15,000 | $18.00 | $270,000.00 |
DisclosureSEC source: 0001415889-22-011983 · form4-12022022_071207.xml · nonDerivative · entry 2 NOYES TIMOTHY P · CIK 0001185035 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 18, 2022. Read SEC document |
| December 01, 2022 Filed Dec 3, 2022 00:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionCommon Stock | 15,000 | $2.14 | $32,100.00 |
DisclosureSEC source: 0001415889-22-011983 · form4-12022022_071207.xml · nonDerivative · entry 1 NOYES TIMOTHY P · CIK 0001185035 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 18, 2022. Read SEC document |
| November 01, 2022 Filed Nov 3, 2022 21:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 1,038 | $19.50 | $20,241.00 |
DisclosureSEC source: 0001415889-22-011067 · form4-11032022_051106.xml · nonDerivative · entry 1 NOYES TIMOTHY P · CIK 0001185035 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 18, 2022. F2 · shares: Includes 1,038 shares purchased under the Issuer's 2021 Employee Stock Purchase Plan on October 31, 2022 in a transaction that is exempt under Rule 16b-3(c) and 16b-3(d). Read SEC document |
| December 14, 2021 Filed Dec 16, 2021 23:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | GrantStock Option (Right to Buy) · Derivative | 204,501 | $0.00 Strike: $10.61 | $0.00 |
DisclosureSEC source: 0001493152-21-031755 · ownership.xml · derivative · entry 1 NOYES TIMOTHY P · CIK 0001185035 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 204,501 Underlying: Common Stock · 204,501 shares Expires 2031-12-13 F1 · derivative.exercise_date: This option shall vest and become exercisable in 48 substantially equal monthly installments, with the first installment vesting on January 14, 2022. Read SEC document |
| June 29, 2021 Filed Jul 1, 2021 22:32 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | GrantStock Option (Right to Buy) · Derivative | 271,200 | $0.00 Strike: $14.00 | $0.00 |
DisclosureSEC source: 0001104659-21-088379 · tm2121189-4_4seq1.xml · derivative · entry 3 NOYES TIMOTHY P · CIK 0001185035 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 271,200 Underlying: Common Stock · 271,200 shares Expires 2031-06-28 F5 · derivative.exercise_date: 25% of this option shall vest and become exercisable on June 29, 2022, with the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| April 02, 2021 Filed Jul 1, 2021 22:32 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | GrantStock Option (Right to Buy) · Derivative | 493,381 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001104659-21-088379 · tm2121189-4_4seq1.xml · derivative · entry 2 NOYES TIMOTHY P · CIK 0001185035 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 493,381 Underlying: Common Stock · 493,381 shares Expires 2031-04-01 F1 · derivative.exercise_price: On June 22, 2021, the Issuer completed a one-for-3.1060103 reverse stock split of the Issuer's Common Stock (the "Reverse Split"). This amount has been adjusted to give effect to the Reverse Split. F2 · kind: This transaction occurred prior to the Issuer's initial public offering, and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3. F1 · shares: On June 22, 2021, the Issuer completed a one-for-3.1060103 reverse stock split of the Issuer's Common Stock (the "Reverse Split"). This amount has been adjusted to give effect to the Reverse Split. F4 · derivative.exercise_date: 25% of this option shall vest and become exercisable on June 4, 2022, with the remainder vesting in 36 substantially equal monthly installments thereafter. F1 · derivative.underlying_shares: On June 22, 2021, the Issuer completed a one-for-3.1060103 reverse stock split of the Issuer's Common Stock (the "Reverse Split"). This amount has been adjusted to give effect to the Reverse Split. F1 · balance_after: On June 22, 2021, the Issuer completed a one-for-3.1060103 reverse stock split of the Issuer's Common Stock (the "Reverse Split"). This amount has been adjusted to give effect to the Reverse Split. Read SEC document |
| April 02, 2021 Filed Jul 1, 2021 22:32 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | GrantStock Option (Right to Buy) · Derivative | 254,253 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001104659-21-088379 · tm2121189-4_4seq1.xml · derivative · entry 1 NOYES TIMOTHY P · CIK 0001185035 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 254,253 Underlying: Common Stock · 254,253 shares Expires 2031-04-01 F1 · derivative.exercise_price: On June 22, 2021, the Issuer completed a one-for-3.1060103 reverse stock split of the Issuer's Common Stock (the "Reverse Split"). This amount has been adjusted to give effect to the Reverse Split. F2 · kind: This transaction occurred prior to the Issuer's initial public offering, and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3. F1 · shares: On June 22, 2021, the Issuer completed a one-for-3.1060103 reverse stock split of the Issuer's Common Stock (the "Reverse Split"). This amount has been adjusted to give effect to the Reverse Split. F3 · derivative.exercise_date: 25% of this option shall vest and become exercisable on February 15, 2022, with the remainder vesting in 36 substantially equal monthly installments thereafter. F1 · derivative.underlying_shares: On June 22, 2021, the Issuer completed a one-for-3.1060103 reverse stock split of the Issuer's Common Stock (the "Reverse Split"). This amount has been adjusted to give effect to the Reverse Split. F1 · balance_after: On June 22, 2021, the Issuer completed a one-for-3.1060103 reverse stock split of the Issuer's Common Stock (the "Reverse Split"). This amount has been adjusted to give effect to the Reverse Split. Read SEC document |
| January 31, 2019 Filed Feb 4, 2019 08:00 UTC | Protara Therapeutics, Inc. PRTO · Entity 6203 | GrantStock Option (Right to Buy) · Derivative | 350,000 | $0.00 Strike: $2.70 | $0.00 |
DisclosureSEC source: 0001171843-19-000681 · ownership.xml · derivative · entry 1 NOYES TIMOTHY P · CIK 0001185035 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350,000 Underlying: Common Stock, $0.001 par value · 350,000 shares Expires 2029-01-30 F1 · derivative.exercise_date: The options were granted on January 31, 2019 and the shares underlying this option vest 25% on the first anniversary of the grant date and the remaining shares vest in twelve equal quarterly installments. Read SEC document |
| February 16, 2018 Filed Feb 20, 2018 08:15 UTC | Protara Therapeutics, Inc. PRTO · Entity 6203 | Disposition to issuerCommon Stock | 2,997 | $2.11 | $6,323.67 |
DisclosureSEC source: 0001171843-18-001229 · formfour.xml · nonDerivative · entry 1 NOYES TIMOTHY P · CIK 0001185035 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 14, 2017. F2 · price: The selling price of $2.11 is reflective of the weighted average sale price of all transactions reported on this line. The prices for the transactions reported on this line range from $2.10 to $2.15. The reporting person undertakes to provide Proteon Therapeutics, Inc., any security holder of Proteon Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 15, 2018 Filed Feb 16, 2018 08:15 UTC | Protara Therapeutics, Inc. PRTO · Entity 6203 | Disposition to issuerCommon Stock | 2,245 | $2.15 | $4,831.24 |
DisclosureSEC source: 0001171843-18-001197 · f4_noyes021618.xml · nonDerivative · entry 2 NOYES TIMOTHY P · CIK 0001185035 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,997 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 14, 2017. F3 · price: The selling price of $2.152 is reflective of the weighted average sale price of all transactions reported on this line. The prices for the transactions reported on this line range from $2.10 to $2.25. The reporting person undertakes to provide Proteon Therapeutics, Inc., any security holder of Proteon Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 14, 2018 Filed Feb 16, 2018 08:15 UTC | Protara Therapeutics, Inc. PRTO · Entity 6203 | Disposition to issuerCommon Stock | 3,500 | $2.20 | $7,700.00 |
DisclosureSEC source: 0001171843-18-001197 · f4_noyes021618.xml · nonDerivative · entry 1 NOYES TIMOTHY P · CIK 0001185035 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,242 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 14, 2017. F2 · price: The selling price of $2.20 is reflective of the weighted average sale price of all transactions reported on this line. The prices for the transactions reported on this line range from $2.20 to $2.23. The reporting person undertakes to provide Proteon Therapeutics, Inc., any security holder of Proteon Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 08, 2018 Filed Feb 9, 2018 08:16 UTC | Protara Therapeutics, Inc. PRTO · Entity 6203 | GrantStock Option (Right to Buy) · Derivative | 500,000 | $0.00 Strike: $2.15 | $0.00 |
DisclosureSEC source: 0001171843-18-001001 · formfour.xml · derivative · entry 1 NOYES TIMOTHY P · CIK 0001185035 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock, $0.001 par value · 500,000 shares Expires 2028-02-07 F1 · derivative.exercise_date: The options were granted on February 8, 2018 and the shares underlying this option vest 25% on the first anniversary of the grant date and the remaining shares vest in twelve equal quarterly installments. Read SEC document |
| January 16, 2018 Filed Jan 17, 2018 17:01 UTC | Protara Therapeutics, Inc. PRTO · Entity 6203 | Disposition to issuerCommon Stock | 10,000 | $2.36 | $23,570.00 |
DisclosureSEC source: 0001171843-18-000401 · formfour.xml · nonDerivative · entry 1 NOYES TIMOTHY P · CIK 0001185035 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,742 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 14, 2017. F2 · price: The selling price of $2.357 is reflective of the weighted average sale price of all transactions reported on this line. The prices for the transactions reported on this line range from $2.30 to $2.425. The reporting person undertakes to provide Proteon Therapeutics, Inc., any security holder of Proteon Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 14, 2017 Filed Dec 15, 2017 17:01 UTC | Protara Therapeutics, Inc. PRTO · Entity 6203 | Disposition to issuerCommon Stock | 10,000 | $1.85 | $18,540.00 |
DisclosureSEC source: 0001171843-17-007706 · formfour.xml · nonDerivative · entry 1 NOYES TIMOTHY P · CIK 0001185035 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,742 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 14, 2017. F2 · price: The selling price of $1.854 is reflective of the weighted average sale price of all transactions reported on this line. The prices for the transactions reported on this line range from $1.85 to $1.925. The reporting person undertakes to provide Proteon Therapeutics, Inc., any security holder of Proteon Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 15, 2017 Filed Nov 16, 2017 17:00 UTC | Protara Therapeutics, Inc. PRTO · Entity 6203 | Disposition to issuerCommon Stock | 5,650 | $1.70 | $9,616.30 |
DisclosureSEC source: 0001171843-17-007112 · formfour.xml · nonDerivative · entry 2 NOYES TIMOTHY P · CIK 0001185035 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,742 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 14, 2017. F3 · price: The selling price of $1.702 is reflective of the weighted average sale price of all transactions reported on this line. The prices for the transactions reported on this line range from $1.65 to $1.725. The reporting person undertakes to provide Proteon Therapeutics, Inc., any security holder of Proteon Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 14, 2017 Filed Nov 16, 2017 17:00 UTC | Protara Therapeutics, Inc. PRTO · Entity 6203 | Disposition to issuerCommon Stock | 4,350 | $1.69 | $7,338.45 |
DisclosureSEC source: 0001171843-17-007112 · formfour.xml · nonDerivative · entry 1 NOYES TIMOTHY P · CIK 0001185035 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,392 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 14, 2017. F2 · price: The selling price of $1.687 is reflective of the weighted average sale price of all transactions reported on this line. The prices for the transactions reported on this line range from $1.65 to $1.80. The reporting person undertakes to provide Proteon Therapeutics, Inc., any security holder of Proteon Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 16, 2017 Filed Oct 17, 2017 16:45 UTC | Protara Therapeutics, Inc. PRTO · Entity 6203 | Disposition to issuerCommon Stock | 10,000 | $2.31 | $23,120.00 |
DisclosureSEC source: 0001171843-17-006105 · formfour.xml · nonDerivative · entry 1 NOYES TIMOTHY P · CIK 0001185035 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,742 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 14, 2017. F2 · price: The selling price of $2.312 is reflective of the weighted average sale price of all transactions reported on this line. The prices for the transactions reported on this line range from $2.25 to $2.35. The reporting person undertakes to provide Proteon Therapeutics, Inc., any security holder of Proteon Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 15, 2017 Filed Sep 18, 2017 16:15 UTC | Protara Therapeutics, Inc. PRTO · Entity 6203 | Disposition to issuerCommon Stock | 5,146 | $1.48 | $7,610.93 |
DisclosureSEC source: 0001171843-17-005589 · formfour.xml · nonDerivative · entry 2 NOYES TIMOTHY P · CIK 0001185035 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,742 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 14, 2017. F3 · price: The selling price of $1.479 is reflective of the weighted average sale price of all transactions reported on this line. The prices for the transactions reported on this line range from $1.475 to $1.50. The reporting person undertakes to provide Proteon Therapeutics, Inc., any security holder of Proteon Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 14, 2017 Filed Sep 18, 2017 16:15 UTC | Protara Therapeutics, Inc. PRTO · Entity 6203 | Disposition to issuerCommon Stock | 4,854 | $1.45 | $7,057.72 |
DisclosureSEC source: 0001171843-17-005589 · formfour.xml · nonDerivative · entry 1 NOYES TIMOTHY P · CIK 0001185035 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,888 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 14, 2017. F2 · price: The selling price of $1.454 is reflective of the weighted average sale price of all transactions reported on this line. The prices for the transactions reported on this line range from $1.425 to $1.475. The reporting person undertakes to provide Proteon Therapeutics, Inc., any security holder of Proteon Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 24, 2017 Filed Jan 26, 2017 08:01 UTC | Protara Therapeutics, Inc. PRTO · Entity 6203 | GrantStock Option (Right to Buy) · Derivative | 122,838 | $0.00 Strike: $2.05 | $0.00 |
DisclosureSEC source: 0001171843-17-000454 · f4_noyes012617.xml · derivative · entry 1 NOYES TIMOTHY P · CIK 0001185035 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,838 Underlying: Common Stock, $0.001 par value · 122,838 shares Expires 2027-01-23 F1 · derivative.exercise_date: The options were granted on January 24, 2017 and the shares underlying this option vest 25% on the first anniversary of the grant date and the remaining shares vest in twelve equal quarterly installments. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.